AllergyTalk

Dr. Vivian Hernandez Trujillo, MD, the Division Director of allergy/immunology at Nickalus Children’s Hospital and an assistant editor of AllergyWatch and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the July/August 2024 issue AllergyWatch.

Articles Reviewed:

The speakers have the following disclosures:

Dr. Lee has been a speaker for Novartis

Read archived issues of AllergyWatch®.

Earn CME credit for listening to this episode! Free for College members!

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

To submit feedback, corrections, and suggestions, please email [email protected]!

The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Welcome to Season Three of Allergytalk!

Today we are joined by Dr. Vivian Hernandez Trujillo, the Division Director of allergy/immunology at Nickalus Children’s Hospital and an assistant editor of Allergy Watch. We will be reviewing the July-August issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

For information about CME credit, head over to http://education.acaai.org/allergytalk

To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

IgE to cross-reactive carbohydrate determinants (CCD) in childhood: Prevalence, risk factors, putative origins. 

Activation of basophils in children with food allergies by blood from donors ingesting the corresponding food.

Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.

Please rate our podcast on Apple Podcasts!

Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has been a speaker for Novartis

Dr. Fineman has nothing to disclose

Dr. Hernandez Trujillo:

Host: Kristin C. Sokol, MD, MS, MPH, FACAAI

Experts: Aleena Banerji, MD; Jonathan A. Bernstein, MD, FACAAI

Explore the strategies for long-term prophylaxis in pediatric HAE, including when to initiate treatment and the risks and benefits of various approaches. Transitioning care from childhood into adolescence and beyond is also discussed.

Learning Objective:

After listening to this podcast episode, participants should be better able to:

References:

Speaker Disclosures:

Kristin C. Sokol, MD, MS, MPH, FACAAI

Advisor: Sanofi, Genentech, SELF/Conde Nast

Aleena Banerji, MD

Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda

Researcher: Astria, Ionis, Intellia

Jonathan A. Bernstein, MD, FACAAI

Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda

Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda

Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva

This podcast miniseries is supported by a grant from Takeda.

Episode 2: Overcoming Barriers in HAE Treatment

Host: Kristin C. Sokol, MD, MS, MPH, FACAAI

Experts: Jonathan A. Bernstein, MD, FACAAI; Timothy J. Craig, DO, FACAAI

This episode addresses the challenges of managing HAE, including treatment differences in rural vs. urban settings, barriers to care, and the importance of shared decision-making for treatment plans. Discover effective strategies for on-demand home therapy administration.

Learning Objective:

After listening to this podcast episode, participants should be better able to:

References:

Speaker Disclosures:

Kristin C. Sokol, MD, MS, MPH, FACAAI

Advisor: Sanofi, Genentech, SELF/Conde Nast

Jonathan A. Bernstein, MD, FACAAI

Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda

Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda

Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva

Timothy J. Craig, DO, FACAAI

Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda

Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda

Independent Contractor: Kalvista, Phavaris

Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda

Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda

This podcast miniseries is supported by a grant from Takeda.

Host: Kristin C. Sokol, MD, MS, MPH, FACAAI

Experts: Aleena Banerji, MD; Timothy J. Craig, DO, FACAAI

This discussion covers the key factors in accurately diagnosing HAE, including clinical history, lab testing, and the role of genetic testing in distinguishing between HAE types. Special considerations for diagnosing pediatric patients will also be discussed.

Learning Objective:

After listening to this podcast episode, participants should be better able to:

References:

Speaker Disclosures:

Kristin C. Sokol, MD, MS, MPH, FACAAI

Advisor: Sanofi, Genentech, SELF/Conde Nast

Aleena Banerji, MD

Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda

Researcher: Astria, Ionis, Intellia

Timothy J. Craig, DO, FACAAI

Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda

Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda

Independent Contractor: Kalvista, Phavaris

Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda

Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda

This podcast miniseries is supported by a grant from Takeda.

Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology!

For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.

You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk.

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

CRISPR Gene-Editing Therapy for Hereditary Angioedema

Reviewed by Samantha knox

CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema.

Longhurst HJ, Lindsay K, Petersen RS, Fijen LM, Gurugama P, Maag D, Butler JS, Shah MY, Golden A, Xu Y, Boiselle C, Vogel JD, Abdelhady AM, Maitland ML, McKee MD, Seitzer J, Han BW, Soukamneuth S, Leonard J, Sepp-Lorenzino L, Clark ED, Lebwohl D, Cohn DM. CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. N Engl J Med. 2024 Feb 1;390(5):432-441. doi: 10.1056/NEJMoa2309149. PMID: 38294975.

New Peanut Allergy Rare After Peanut Introduction in Infants

Reviewed by Sarah Spriet

Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants

Banerjee A, Wood R, Dunlop J, Dantzer J, Plesa M, Togias A, Keet C. Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants. J Allergy Clin Immunol Pract. 2024 Mar;12(3):645-651.e1. doi: 10.1016/j.jaip.2023.11.035. Epub 2023 Nov 29. PMID: 38036248.

IgE to Food Allergens and Cardiovascular Mortality

Reviewed by Gerry Lee

IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis

Keet C, McGowan EC, Jacobs D, Post WS, Richards NE, Workman LJ, Platts-Mills TAE, Manichaikul A, Wilson JM. IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis. J Allergy Clin Immunol. 2024 Feb;153(2):471-478.e3. doi: 10.1016/j.jaci.2023.09.038. Epub 2023 Nov 9. PMID: 37943208; PMCID: PMC10922097.

Please rate our podcast on Apple podcasts!

Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

You can also earn CME credit by listening to this podcast! For information about CME credit head over to education.acaai.org/allergywatch. If you want to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has been a speaker for Novartis

Dr. Fineman has nothing to disclose

Dr. Chow has been an advisor for Sarepta Therapeutics (relationship has ended KA)

Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology!

For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.

You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk.

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Reviewed by Iris Otani

Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial.

Zhang J, Yang X, Chen G, Hu J, He Y, Ma J, Ma Z, Chen H, Huang Y, Wu Q, Liu Y, Yu L, Zhang H, Lai H, Zhang J, Zhai J, Huang M, Zou Z, Tao A. Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial. Ann Allergy Asthma Immunol. 2024 Mar;132(3):346-354.e1. doi: 10.1016/j.anai.2023.10.029. Epub 2023 Oct 31. PMID: 37913839.

Clinical Remission in a Real-World Severe Asthma Registry

Reviewed by Tim Chow

Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry.

McDowell PJ, McDowell R, Busby J, Eastwood MC, Patel PH, Jackson DJ, Mansur A, Patel M, Burhan H, Doe S, Chaudhuri R, Gore R, Dodd JW, Subramanian D, Brown T, Heaney LG; UK Severe Asthma Registry. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J. 2023 Dec 14;62(6):2300819. doi: 10.1183/13993003.00819-2023. PMID: 37857423; PMCID: PMC10719453.

More Evidence Against Using Corticosteroids for Anaphylaxis

Reviewed by Iris Otani

Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphylaxis REgistry data.

Delli Colli L, Al Ali A, Gabrielli S, Delli Colli M, Mule P, Lawson B, Clarke AE, Morris J, Gravel J, Lim R, Chan ES, Goldman RD, O'Keefe A, Gerdts J, Chu DK, Upton J, Hochstadter E, Bretholz A, McCusker C, Zhang X, Benor S, Simons E, Abrams EM, Protudjer JLP, Ben-Shoshan M. Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphylaxis REgistry data. Ann Allergy Asthma Immunol. 2023 Dec;131(6):752-758.e1. doi: 10.1016/j.anai.2023.08.606. Epub 2023 Sep 7. PMID: 37689113.

Please rate our podcast on Apple podcasts!

Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

You can also earn CME credit by listening to this podcast! For information about CME credit head over to education.acaai.org/allergywatch. If you want to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has been a speaker for Novartis

Dr. Fineman has nothing to disclose

Dr. Chow has been an advisor for Sarepta Therapeutics (relationship has ended)

The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries

Episode 3: Maintenance and Reliever Therapy in Moderate to Severe Asthma

Host: Gerald B. Lee, MD, FACAAI

Experts: Leonard B. Bacharier, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI

Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: MART therapy, ICS/formoterol, FDA guidelines, pediatric application.

Learning Objectives:

• Expose the prevalence of asthma and exacerbations in the US

Speaker Disclosures:

Gerald B. Lee, MD, FACAAI

No relevant financial relationships with ineligible companies to disclose

Leonard B. Bacharier, MD, FACAAI

Advisor: DBV Technologies

Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi

Researcher: AstraZeneca, Sanofi

Speaker: Regeneron, Sanofi

Alan P. Baptist, MD, MPH, FACAAI

Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi

Researcher: AstraZeneca, Novartis, Regeneron

This podcast miniseries is supported by a grant from AstraZeneca.

The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries

Episode 2: Implementing an Anti-inflammatory Reliever in Mild Asthma

Host: Gerald B. Lee, MD, FACAAI

Experts: William C. Anderson III, MD, FACAAI, Leonard B. Bacharier, MD, FACAAI

Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: anti-inflammatory reliever (AIR), pediatric vs. adult patients, GINA guidelines, insurance challenges.

Learning Objectives:

• Expose the prevalence of asthma and exacerbations in the US

Reference:

Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.

Speaker Disclosures:

Gerald B. Lee, MD, FACAAI

No relevant financial relationships with ineligible companies to disclose

William C. Anderson III, MD, FACAAI

Advisor: Genentech, Regeneron, Sanofi

Leonard B. Bacharier, MD, FACAAI

Advisor: DBV Technologies

Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi

Researcher: AstraZeneca, Sanofi

Speaker: Regeneron, Sanofi

This podcast miniseries is supported by a grant from AstraZeneca.

The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries

Episode 1: The Limitations of Bronchodilator Only Rescue Therapy

Host: Gerald B. Lee, MD, FACAAI

Experts: William C. Anderson III, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI

Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: pathophysiology, exacerbations, anti-inflammatory reliever (AIR), SMART therapy.

Learning Objectives:

• Expose the prevalence of asthma and exacerbations in the US

Reference:

Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.

Speaker Disclosures:

Gerald B. Lee, MD, FACAAI

No relevant financial relationships with ineligible companies to disclose

William C. Anderson III, MD, FACAAI

Advisor: Genentech, Regeneron, Sanofi

Alan P. Baptist, MD, MPH, FACAAI

Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi

Researcher: AstraZeneca, Novartis, Regeneron

This podcast miniseries is supported by a grant from AstraZeneca.